{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "firstTradeDateMilliseconds": 1652794200000, "priceHint": 4, "exchange": "NCM", "shortName": "OKYO Pharma Limited", "longName": "OKYO Pharma Limited", "messageBoardId": "finmb_45535051", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.870972, "regularMarketPrice": 1.61, "marketState": "PRE", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 0.060000062, "regularMarketTime": 1684180805, "regularMarketDayHigh": 1.73, "regularMarketDayRange": "1.5 - 1.73", "regularMarketDayLow": 1.5, "regularMarketVolume": 59443, "regularMarketPreviousClose": 1.55, "bid": 0.0, "ask": 0.0, "bidSize": 13, "askSize": 9, "fullExchangeName": "NasdaqCM", "financialCurrency": "GBP", "regularMarketOpen": 1.54, "averageDailyVolume3Month": 745621, "averageDailyVolume10Day": 398510, "fiftyTwoWeekLowChange": 0.51, "fiftyTwoWeekLowChangePercent": 0.46363634, "fiftyTwoWeekRange": "1.1 - 7.0", "fiftyTwoWeekHighChange": -5.39, "fiftyTwoWeekHighChangePercent": -0.77, "fiftyTwoWeekLow": 1.1, "fiftyTwoWeekHigh": 7.0, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.65, "sharesOutstanding": 25519900, "bookValue": 0.0, "fiftyDayAverage": 1.5844, "fiftyDayAverageChange": 0.025599957, "fiftyDayAverageChangePercent": 0.016157508, "twoHundredDayAverage": 2.136245, "twoHundredDayAverageChange": -0.526245, "twoHundredDayAverageChangePercent": -0.24634112, "marketCap": 46574884, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "displayName": "OKYO Pharma", "symbol": "OKYO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "14/15 Conduit St", "address2": "Floor 4", "city": "London", "zip": "W1S 2XJ", "country": "United Kingdom", "phone": "44 20 7495 2379", "website": "https://www.okyopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gary S. Jacob Ph.D.", "age": 75, "title": "CEO & Exec. Director", "yearBorn": 1947, "fiscalYear": 2022, "totalPay": {"raw": 387195, "fmt": "387.19k", "longFmt": "387,195"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 186750, "fmt": "186.75k", "longFmt": "186,750"}}, {"maxAge": 1, "name": "Mr. Michael Paul Beck", "age": 65, "title": "Founder", "yearBorn": 1957, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Keeren  Shah", "age": 45, "title": "Chief Financial Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Rajkumar  Patil Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1958, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}